Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MacroGenics, a biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, has raised $25 million in a series D-2 financing.
Subscribe to our email newsletter
The round, led by Nextech Venture, included additional new investors Arcus Ventures, Innovis Investments and Eli Lilly and Company. Also participating in the financing were existing investors Alexandria Real Estate, Alta Partners, CIDC, InterWest Partners, Mitsubishi UFJ, OrbiMed Advisors, Red Abbey Venture Partners, RiverVest, Texas Pacific Group Ventures and Ventures West.
MacroGenics expects to use the proceeds from this financing to fund the cancer stem cell program it acquired through its acquisition of Raven Biotechnologies in July 2008. In addition, the proceeds will be used to further advance the company’s autoimmune, cancer and infectious disease product candidate portfolio, as well as for general working capital purposes.
MacroGenics’s most advanced product candidate is teplizumab, which is being developed in partnership with Eli Lilly and Company. Teplizumab is currently being studied in the Protege trial, a global pivotal Phase II/III clinical trial for individuals with recent-onset type 1 diabetes.
Scott Koenig, president and CEO of MacroGenics, said: “We are delighted to add Nextech Venture, Arcus Ventures and Innovis Investments, three oncology-focused investors, as well as Eli Lilly and Company to our roster of blue chip shareholders. Our experienced investor syndicate provides critical support to MacroGenics as we drive our programs through clinical development towards commercialization.”